GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Short Interest

Cellectis (LTS:0WA2) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cellectis's Short Interest

For the Biotechnology subindustry, Cellectis's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Short Interest distribution charts can be found below:

* The bar in red indicates where Cellectis's Short Interest falls into.


;
;

Cellectis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Short Interest
Comparable Companies
XPAR:IPH XPAR:NANO XPAR:IVA XPAR:GNFT XPAR:OSE XPAR:ALSEN XPAR:DBV XPAR:TNG XPAR:MAAT XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CLLS:USA ALCLS:France ZVAA:Germany
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Website
https://www.cellectis.com
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines